Get all premium features to the best stock analysis tool

NEW YORK, Sept. 26, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds persons or entities that: (a) sold shares of Dun & Bradstreet Holdings, Inc. (NYSE: DNB) (“D&B”) common stock in the open market from May 13, 2025 through August 26, 2025; (b) exchanged shares of D&B common stock into the August 26, 2025 merger of D&B with affiliates of Clearlake Capital Group, L.P. for $9.15 per share in cash (the “Merger”); and/or (c) held shares of D&B common stock as of the May 9, 2025 Record Date for the special meeting of stockholders and whose shares were voted on, or entitled to vote on, the Merger, of the important November 10, 2026 lead plaintiff deadline.

Costco treats its workers, customers, and shareholders well. It's a dividend-paying stock.

Waters NYSE: WAT President and Chief Executive Officer Udit Batra said the company's second-quarter performance exceeded expectations, supported by broad-based growth in its legacy analytical-science operations and early progress integrating acquired Becton Dickinson businesses.

President Donald Trump has approved new fuel economy standards, he said in a Truth Social post. The new standards will reverse the Biden administration's stricter policies that were expected to increase fuel efficiency and encourage greater use of EV and hybrid technology.

Boeing said it flagged a software glitch last month on some 737 Max aircraft. The software problem could affect certain landing procedures.

NEW YORK, Sept. 26, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Wise Group plc (NASDAQ: WSE) between May 11, 2026 and July 23, 2026, both dates inclusive (the "Class Period"), of the important September 29, 2026 lead plaintiff deadline in the securities class action first filed by the Firm.

MPLX has a higher dividend yield than Energy Transfer and has a longer record of dividend increases. Energy Transfer has raised its dividend for 19 consecutive quarters.

AC Immune NASDAQ: ACIU reported results from Part 1 of its VacSYn Phase II trial evaluating ACI-7104.056, an active immunotherapy designed to target aggregated alpha-synuclein in early Parkinson's disease.